HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company
[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to announce a...
July 18, 2023
[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to announce a...
March 4, 2023
SAN JOSE, Calif., and UTRECHT, Netherlands, Feb. 13, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, and...
April 28, 2022
Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do...
November 10, 2021
Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview of the...
September 2, 2021
2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial leaders in...
August 31, 2021
HUB Organoids derived from patients with chronic hepatitis B show the first molecular signs of liver cancer. The molecular events that drive...
August 18, 2021
VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use...
August 12, 2021
HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF). HUB Organoids™ advance treatment for...